Identification of Novel Cyclobutane-Based Derivatives as Potent Acetyl-CoA Carboxylase Allosteric Inhibitors for Nonalcoholic Steatohepatitis Drug Discovery

Nonalcoholic steatohepatitis (NASH) has become a leading cause of liver fibrosis and hepatocellular carcinoma; however, there are no efficient drugs for NASH therapy. Acetyl-CoA carboxylase (ACC) is a crucial enzyme regulating lipid metabolism that is considered as a potential target for NASH treatm...

Full description

Saved in:

Bibliographic Details
Main Author:	Yazhou Wang (1508368) (author)
Other Authors:	Hai Wang (310051) (author), Qingqing Li (1505614) (author), Ying Zhang (40767) (author), Rupeng Dai (7817822) (author), Jun Wu (4002) (author), Yanan Zhang (1322391) (author), Xiaomeng Zhang (182897) (author), Liwen Zhao (2886926) (author), Jian Liu (33711) (author)
Published:	2025
Subjects:	Biochemistry Medicine Genetics Molecular Biology Pharmacology Biotechnology Infectious Diseases Virology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified Information Systems not elsewhere classified potent therapeutic effect several hotspot residues b1 </ b hotspot residues several cyclobutane vivo </ vitro </ protein families promising candidate potential target potent acetyl novel cyclobutane leading cause initially identified important source highly variable higher distribution hepatocellular carcinoma gbsa calculation efficient drugs drug candidates coa carboxylase biologically evaluated based derivatives allosteric inhibitors alanine mutation
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Identification of Novel Cyclobutane-Based Derivatives as Potent Acetyl-CoA Carboxylase Allosteric Inhibitors for Nonalcoholic Steatohepatitis Drug Discovery

Similar Items